SGLT2 inhibitors are a class of prescription drugs that block glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine. This lowers blood sugar, promotes a mild state of ketosis, and reduces blood pressure, mimicking some of the metabolic effects of caloric restriction. Their proven cardiovascular and renal protective benefits, even in non-diabetics, make them a significant intervention for healthspan.
Verdict
High-impact metabolic intervention with robust evidence but requires medical supervision.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$50 - $500
Protocol
- Daily low-dose empagliflozin (10mg) or canagliflozin (100mg) is a common off-label approach.
Flags
- Requires a prescription and ongoing medical supervision.
- Increased risk of urinary tract and genital yeast infections due to glucosuria.
- Carries a rare but serious risk of euglycemic ketoacidosis (eKA), especially with low-carb diets or illness.
- May cause dehydration or hypotension; adequate hydration is crucial.
- Interacts with diuretics and may require dose adjustments for insulin or sulfonylureas.